NC-531 (Alzhemed, Cerebril)

Indications

• Alzheimer's disease (Phase 3 trials, 07/04)
• hemorrhagic stroke due to cerebral amyloid angiopathy

Dosage

• 300 mg PO QD

Pharmacokinetics

• crosses blood-brain barrier (found in CSF)

Adverse effects

• mild, no serious adverse effects noted
• nausea/vomiting
• GI distress

Mechanism of action

• sulfated glycosaminoglycan mimetic
• modifies association of Abeta with glycosaminoglycans
• inhibits amyloid plaque formation
  • binds & diminishes soluble Abeta
  • inhibits Abeta fibrillization
• may inhibit inflammatory response associated with amyloid plaques

Notes

Neurochem Inc (Canada)

More general terms

• miscellaneous pharmacologic agent